Higher Prostate Cancer risk linked to Inflammatory Bowel Disease


Men with inflammatory bowel disease (IBD) are at elevated risk of prostate cancer (PCa) overall as well as clinically significant PCa

In a retrospective study comparing 1033 men with IBD and 9306 men without IBD matched by age and race (controls), investigators found that the 10-year incidence of any PCa was 4.4% in the IBD group compared with 0.65% in the control arm. The 10-year incidence of clinically significant PCa-defined as Gleason grade group 2 or higher-was 2.4% in the IBD group compared with 0.42% among controls. In adjusted analyses, the presence of IBD, compared with its absence, was associated with a significant 4.8- and 4.0-fold increased risk of any PCa and clinically significant PCa, respectively. In addition, the study revealed that after about age 60, PSA values were higher among patients with than without IBD.

It is conceivable that the local or systemic inflammatory state resulting from IBD may lead to chronic prostatic inflammation and, in some cases, eventual development of PCa.

Moreover, both PCa and IBD have significant genetic predispositions. Genome-wide association studies have identified numerous susceptibility alleles for IBD and PCa, they pointed out. "Shared risk alleles could partially explain the association between IBD and PCa.


Burns JA, Weiner AB, Catalona WJ, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2018; published online ahead of print.